The report has brought to attention the increasing danger of bacteria that are resistant to modern medicine. This problem has already reached alarming levels in many areas of the world.
Thierry Mauvernay
Advertisement
Mr. Mauvernay is the president of Debiopharm, a Swiss, privately owned biopharmaceutical company founded by his father over 40 years ago. With 15 ongoing drug research programs, Debiopharm has developed two therapies for cancer patients, oxaliplatin and triptorelin, and a potential 3rd head & neck cancer drug currently in phase III development with an international partner. Mr. Mauvernay aspires to bring curative drug therapies and visionary health care solutions to patients worldwide.
Articles by Thierry Mauvernay
Advertisement
Latest Updated Articles
Antimicrobial Resistance Is the Health Threat We Cannot IgnorePublished: August 2nd 2023 | Updated:
Advertisement
Advertisement
Trending on Infection Control Today
1
Unusual Surge in Hand, Foot, and Mouth Disease Raises Public Health Concerns
2
Building a Culture of Safety: Experts Call for a Reboot on Stethoscope Hygiene and Everyday Infection Risks
3
Rethinking Linens: Experts Highlight a Missing Piece of Infection Prevention
4
